Historically, xylazine has been utilized in veterinary medicine for decades as an anesthetic and analgesic sedative to facilitate safe handling, diagnostic testing, and surgical procedures in large animals. Currently, xylazine is an emerging threat to human health. It has been detected in the illicit drug supply chain, often as an adulterant. It has been more commonly added to illicit substances, most notably fentanyl, by drugmakers to enhance drug effect. End users are often unaware of its presence. This is alarming given the large number of xylazine-involved overdose deaths while laboratory detections are deficient and reversal agents are absent. Herein, we present the first documented case of xylazine identified via gas chromatography-tandem mass spectrometry at University of California Davis Health despite a peculiarly mild clinical presentation. We hope to increase awareness of this potentially fatal adulterant that is often missed in evaluation and engender further opportunities to study this ongoing issue.
Fentanyl , Fentanyl/analogs & derivatives , Xylazine , Fentanyl/analysis , Fentanyl/administration & dosage , Xylazine/adverse effects , Humans , Male , Drug Contamination , Gas Chromatography-Mass Spectrometry , Drug Overdose/diagnosis , Analgesics, Opioid/analysis , Tandem Mass Spectrometry/methods
